Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 24;4(2):381–392. doi: 10.1002/jha2.663

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

(A) Overall survival of venetoclax and decitabine or azacitidine was 6.0 months. (B) Median overall survival of decitabine‐venetoclax was 8.3 months versus 2.6 months with venetoclax (p = 0.080). (C) Median overall survival of the de novo acute myeloid leukemia (AML) cohort was 11.5 months versus 6.0 months in the MDS/AML‐MRC group (p = 0.01). D. Median overall survival was 17.7 months for measurable residual disease (MRD) negative versus 8.2 months for MRD positive (p = 0.01). E. Median overall survival was 8.6 months for Eastern Cooperative Oncology Group (ECOG) 0–1 versus 4.6 months for ECOG 2–3 (p = 0.034). F. Median overall survival of CCI score ≤7 (8.2 months) versus > 7 (2.1 months) (p = 0.002).